Key Stats for Zoetis Stock
- 52-Week Range: $132 to $172
- Current Price: $116
- Street Mean Target: $150
- Street High Target: $190
- TIKR Model Target (Dec. 2030): $171
What Happened?
Zoetis (ZTS), the world’s largest pure-play animal health company serving both companion animals and livestock across more than 100 countries, is trading near a two-year low at $116.06 despite delivering 6% organic operational revenue growth in 2025 and issuing 2026 guidance ahead of Wall Street expectations.
The catalyst for the stock’s roughly 33% decline from its 52-week high was the Q4 2025 earnings call in February, where management reported that U.S. companion animal therapeutic visits had declined as Gen Z and Millennial pet owners pulled back on routine and wellness care in response to veterinary clinic price increases that had run well above inflation for several consecutive years.
Zoetis is also absorbing the competitive launch of Numelvi, Merck’s oral JAK inhibitor for canine atopic dermatitis that received U.S. approval in late February, entering a market where Zoetis already holds more than $1.7 billion in annual key dermatology revenue anchored by Apoquel, Apoquel Chewable, and Cytopoint.
Despite those near-term headwinds, the full-year 2025 Simparica franchise, which encompasses the canine parasiticide Simparica Trio and standalone Simparica, grew 12% operationally to $1.5 billion, with Simparica Trio surpassing $1 billion in U.S. sales alone.
CEO Kristin Peck stated on the Q4 2025 earnings call that “this is not a decline in underlying demand for care, but rather greater price sensitivity and tighter household budgets when it comes to the cost of routine care,” framing the U.S. softness as a cyclical pricing correction rather than a structural break in the human-animal bond.
On March 2, Zoetis announced a $160 million agreement to acquire Neogen’s animal genomics business, which operates five laboratories across the U.S., Brazil, Australia, China, and the U.K. and serves customers in more than 120 countries, deepening the company’s data infrastructure for precision animal health ahead of planned launches in chronic kidney disease, oncology, and cardiology.
Wall Street’s Take on ZTS Stock
The Q4 beat and above-consensus 2026 guidance are only half the story — the more important development is that ZTS delivered them while absorbing a U.S. companion animal deceleration that investors had feared would be far more severe, setting a floor under forward estimates.
ZTS posted normalized EPS of $6.41 in 2025, up 8.3%, and consensus estimates now point to around $7 for 2026 — a further gain of around 10% anchored by livestock mid-single-digit growth and a Simparica franchise holding its position as the global parasiticide leader despite a competitive entry.
Twelve analysts hold buy or outperform ratings on ZTS, against eight holds and zero sells, with a mean price target of $150.29, implying roughly 30% upside from current levels — a gap that reflects Wall Street’s view that the companion animal macro headwinds are transient, not structural.
The spread from $127 to $190 across analyst targets captures a genuine debate: the low end prices in a prolonged dermatology market share loss and a slower-than-guided OA pain recovery, while the high end reflects the bull case that triple-combination parasiticides keep expanding and that Lenivia and Cytopoint long-acting approvals catalyze a re-rating in 2027.
Priced at roughly 16.5x 2026 consensus EPS against a five-year historical forward P/E that averaged well above 30x, and with EPS tracking around 10% annual growth despite a year of peak competitive pressure, Zoetis stock appears undervalued relative to its own history and relative to the pace at which its core franchises continue compounding.
If U.S. veterinary clinic price moderation stalls and Gen Z pet owner visits do not recover through the second half of 2026 as management projects, the bear case for the Simparica and dermatology franchises gets meaningfully worse.
The number to watch at the Q1 2026 earnings call in May is U.S. companion animal revenue growth: any return to positive territory versus the flat-to-negative Q4 2025 reading would confirm that the macro floor management described is holding.
What Does the Valuation Model Say?
The TIKR mid-case model targets $171 for ZTS by December 2030 on a 5.4% revenue CAGR and a 6.6% EPS CAGR assumption, implying that even modest top-line reacceleration from the 2025–2026 trough unlocks a 47% total return from current levels over roughly five years.
At around 16.5x forward EPS while the business compounds earnings at around 10% annually, Zoetis stock appears undervalued — the model’s mid-case annualized return of around 9% assumes no valuation multiple expansion, meaning the upside is driven entirely by earnings growth, not a re-rating.
The tension in the Zoetis investment case is not whether the franchise is durable — it is whether the 2026 trough is shallow enough that the pipeline catalysts in 2027 and 2028 arrive before investors lose patience.
What Has to Go Right
- U.S. companion animal visit trends stabilize in H2 2026, confirming CEO Peck’s view that the consumer correction is pricing-driven, not demand-driven, and validating the around 3% to 5% organic growth guide
- Lenivia and Portela (long-acting OA pain products for dogs and cats launching in the EU and Canada in H1 2026, U.S. approval targeted for 2027) replicate Librela’s early satisfaction levels without the safety perception headwinds that weighed on the existing franchise
- Cytopoint long-acting approval, targeted for late 2026, extends the dermatology franchise runway before the IL-31 competitor can establish meaningful share in the injectable segment
- Chronic kidney disease assets, targeting a TAM management estimates at $3 billion to $4 billion, reach approval in the 2027 time frame, providing a new growth category with no existing competition
What Could Go Wrong
- Numelvi and a second oral JAK competitor in U.S. dermatology combine to compress Apoquel and Apoquel Chewable revenue faster than the $1.7 billion base implies, eroding the franchise that drives the largest share of companion animal profitability
- Librela’s U.S. OA pain recovery extends into 2027 rather than the back half of 2026, as stabilizing sequential trends in Q4 2025 reverse if macro pressure on therapeutic visits intensifies
- Simparica Trio faces a credible triple-combination entrant, with the 50% current clinic patient share for triple combinations offering a ceiling rather than a floor if switching dynamics accelerate
- The Neogen genomics acquisition and chronic kidney disease pipeline spending pressure margins at the same time that top-line growth is running below the 8% to 9% long-run average, limiting the P/E re-rating the bull case depends on
Should You Invest in Zoetis Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ZTS stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Zoetis Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ZTS stock on TIKR for Free →
